Anhui Anke BioTech Group
Anhui Anke Biotechnology (Group) Co., Ltd. engages in the biopharmaceutical industry in China and internationally. The company offers human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterf… Read more
Anhui Anke BioTech Group (300009) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.055x
Based on the latest financial reports, Anhui Anke BioTech Group (300009) has a cash flow conversion efficiency ratio of 0.055x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥240.51 Million) by net assets (CN¥4.34 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Anhui Anke BioTech Group - Cash Flow Conversion Efficiency Trend (2006–2024)
This chart illustrates how Anhui Anke BioTech Group's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Anhui Anke BioTech Group Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Anhui Anke BioTech Group ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MMG Limited
PINK:MMLTF
|
0.197x |
|
Bossard Holding AG
OTCGREY:BHAGF
|
0.027x |
|
Teijin Limited
F:TIJ
|
N/A |
|
China TransInfo Technology Co Ltd
SHE:002373
|
0.022x |
|
Ivanhoe Electric Inc.
NYSE MKT:IE
|
-0.094x |
|
Beijing Jingneng Power Co Ltd
SHG:600578
|
0.127x |
|
Vermilion Energy Inc.
NYSE:VET
|
0.144x |
|
Margun Enerji Uretim Sanayi ve Ticaret AS
IS:MAGEN
|
-0.037x |
Annual Cash Flow Conversion Efficiency for Anhui Anke BioTech Group (2006–2024)
The table below shows the annual cash flow conversion efficiency of Anhui Anke BioTech Group from 2006 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥4.30 Billion | CN¥685.37 Million | 0.159x | -36.37% |
| 2023-12-31 | CN¥3.93 Billion | CN¥985.01 Million | 0.250x | +21.91% |
| 2022-12-31 | CN¥3.40 Billion | CN¥698.98 Million | 0.205x | +0.75% |
| 2021-12-31 | CN¥2.90 Billion | CN¥592.17 Million | 0.204x | +28.50% |
| 2020-12-31 | CN¥2.93 Billion | CN¥464.80 Million | 0.159x | +44.95% |
| 2019-12-31 | CN¥2.70 Billion | CN¥295.63 Million | 0.109x | -23.41% |
| 2018-12-31 | CN¥2.01 Billion | CN¥287.49 Million | 0.143x | -10.32% |
| 2017-12-31 | CN¥1.76 Billion | CN¥280.63 Million | 0.159x | -11.88% |
| 2016-12-31 | CN¥1.43 Billion | CN¥258.01 Million | 0.181x | +92.66% |
| 2015-12-31 | CN¥1.26 Billion | CN¥118.73 Million | 0.094x | -33.17% |
| 2014-12-31 | CN¥773.47 Million | CN¥108.68 Million | 0.141x | +74.44% |
| 2013-12-31 | CN¥660.60 Million | CN¥53.21 Million | 0.081x | -13.16% |
| 2012-12-31 | CN¥580.03 Million | CN¥53.80 Million | 0.093x | +602.56% |
| 2011-12-31 | CN¥543.88 Million | CN¥7.18 Million | 0.013x | -85.46% |
| 2010-12-31 | CN¥522.30 Million | CN¥47.43 Million | 0.091x | +16.32% |
| 2009-12-31 | CN¥495.41 Million | CN¥38.67 Million | 0.078x | -55.44% |
| 2008-12-31 | CN¥148.64 Million | CN¥26.04 Million | 0.175x | -31.56% |
| 2007-12-31 | CN¥137.09 Million | CN¥35.10 Million | 0.256x | +5.30% |
| 2006-12-31 | CN¥122.00 Million | CN¥29.66 Million | 0.243x | -- |